In the pursuit of a healthier and more fulfilling life, exercise plays a pivotal role. Among the diverse forms of exercise, resistance training stands...
Lupin and Mylan Launch Nepexto®, Biosimilar Etanercept in GermanyFriday August 28, 2020 at 1:25 am
Mumbai, India | BAD HOMBURG, Germany, August 26, 2020: Lupin Limited (Lupin) and Mylan N.V. (NASDAQ: MYL) announced today the launch of Nepexto®, biosimilar etanercept, in the German market. Nepexto® is indicated for the treatment of moderate to severely active rheumatoid arthritis, juvenile idiopathic arthritis from the age of 2 years, active and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis and chronic severe plaque psoriasis in children and adolescents from the age of 6 years. Nepexto® is approved for all therapeutic indications of the reference product Enbrel®.
Etanercept as an established therapy option
The Tumor Necrosis Factor (TNF) inhibitor etanercept was first approved for the treatment of rheumatoid arthritis in Germany in 2000 and since then has offered an effective treatment option for several chronic inflammatory diseases.
“TNF inhibitors such as etanercept make it possible to intervene precisely in the inflammatory process,” commented Prof. Dr. med. Rieke Alten, chief physician in the Department of Internal Medicine (Rheumatology, Clinical Immunology, Osteology) at the Schlosspark-Klinik Charlottenburg, Berlin. “In patients with moderately severe to severe rheumatoid arthritis who do not respond adequately to basic therapeutics, remission of the disease through therapy with etanercept in combination with methotrexate is a quite realistic therapeutic goal. Rheumatologists have many years of clinical experience with this substance in terms of its efficacy and safety profile. Rheumatologists particularly like to opt for etanercept when ‘safety first’ is the top priority. Besides rheumatoid arthritis, this TNF inhibitor is also firmly established in other rheumatological indications.”
Simple application by means of pre-filled pen
Nepexto® is available as a solution for injection in a pre-filled pen and prefilled syringe. Data show a high patient acceptance of the easy-to-handle pre-filled pen. Patients favored this latex-free device for self-injection, which can lead to an improvement in compliance.
Cost-effective treatment with Nepexto®
Nepexto®, with equivalent efficacy and safety to reference product Enbrel®, is an attractive cost-effective treatment alternative that can contribute to sustainable healthcare and treatment options. The European Commission approved the marketing authorization of Nepexto® on June 4, 2020 after the biosimilar received a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP). The CHMP concluded that the development program including analytical, functional, clinical and immunogenicity data, demonstrated bio-similarity with its reference product, Enbrel®.
Thierry Volle, President, EMEA, Lupin said, “We are excited to bring Nepexto® in Germany. Nepexto® is our first biosimilar to receive regulatory approval in Europe. This launch is a remarkable milestone for our biosimilar group and we are glad that we are able to bring an affordable biosimilar to the European market through our partner Mylan. Biosimilars like Nepexto® will play a vital role in expanding access to effective treatment for multiple therapies including rheumatoid arthritis.”
Dr. Maximilian von Wülfing, Managing Director of Mylan Germany said, “Germany is the first country in Europe to introduce Nepexto®, the etanercept from Mylan. The approval of Nepexto® (etanercept) by the European Medicines Agency (EMA) once again underlines the scientific success of Mylan’s biologics program. To date Mylan has launched and commercialized four biosimilar products in Germany, two in immunology and two in oncology. Mylan offers a comprehensive and diverse biologics pipeline, and we want to make as many of these complex drugs as possible available to patients in Germany.”
Nepexto is the second immunology product to be introduced into the German market. In addition to Hulio®, an adalimumab biosimilar, Nepexto® expands Mylan’s therapeutic portfolio for the effective treatment of various immune-mediated diseases including rheumatoid arthritis.